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OBJECTIVES: The probability of contracting a hospital acquired infection increases
the longer an individual is hospitalised. The purpose of this analysis is to quantify
the additional probability of contracting Clostridium Difficile Infection (CDI) for each
additional day spent in the hospital.METHODS:Using the English Hospital Episode
Statistics (HES) database, the number of inpatient days before diagnosis of hospi-
tal-acquired CDI and the total number of inpatient days for patients that do not
acquire CDI are calculated. This time-to-event variable, along with a set of covari-
ates, is used in a binary logistic regression to predict the added probability of
contracting CDI for each additional day in the hospital. Patients in this analysis
were over 50 years old, had a length of stay (LoS) less than 50 days, and had a
co-morbidity of chronic obstructive pulmonary disease (COPD), heart failure, dia-
betes, or kidney disease. RESULTS: The average LoS for all patients, patients with
CDI, and patients without CDI, was 5.48 days (28.46), 26.24 days (212.86), and
5.38 days (28.46), respectively. The average LoS before acquiring CDI was 6.27
days (212.81). For each additional day spent in the hospital, a patient has 4.40%
greater chance of contracting the disease (OR1.044; s.e.0.001; p0.01). Increased
age (OR1.134; s.e.0.019; P0.01) and being female (OR1.28; s.e.0.034; p0.01)
were also predictors of CDI diagnosis. CONCLUSIONS: This model quantifies the
increased likelihood of hospital acquired infections associated with longer dura-
tion inpatient admissions. Such infections are associated with much more severe
health outcomes and are a significant burden on hospital resources.
PIN3
BURDEN OF CYTOMEGALOVIRUS DISEASE IN IMMUNOSUPPRESSED PERSONS
FOLLOWING TRANSPLANTATION IN FRANCE
Goryakin Y1, Ferchichi S2, Skanji D2, Odeyemi II3, Hakimi Z4, Aballea S5
1Creativ Ceutical, London, UK, 2Creativ Ceutical, Tunis, Tunisia, 3Astellas Pharma Europe Ltd.,
Middlesex, UK, 4Astellas Pharma Global Development, Leiderdorp, UK, 5Creativ-Ceutical, Paris,
France
OBJECTIVES: Following solid organ transplantation (SOT) or hematopoietic stem
cell transplantation (HSCT), patients are at risk of cytomegalovirus (CMV) disease.
The impact of CMV disease on mortality and hospitalisation costs following trans-
plantation and on the probability of transplant rejection following SOT was
estimated. METHODS: We conducted a retrospective cohort study of a database of
hospitalisations in France (PMSI). Available data included demographics, hospital
characteristics, diagnoses, health care procedures, length of stay, discharge status
and costs. Logistic regression was used to estimate the impact of CMV disease
during initial hospitalisation on the probability of graft rejection and mortality
during initial stay or following readmission. The impact of CMV disease on costs
was estimated using generalised linear modelling. All estimates were adjusted on
age, gender and transplant type. A first analysis based on hospitalisation records
from 2007 was performed; additional analyses accounting for patient censoring,
with the data from 2008 to 2011, are planned. RESULTS: Among 4,078 SOT recipi-
ents and 3,530 HSCT recipients, CMV disease was reported during initial stay in 65
(1.59%) and 67 (1.90%) patients respectively. Case fatality rates were 5.37% and
3.23% in the SOT and HSCT recipients. CMV disease was associated with an in-
creased mortality following HSCT (odds ratio  3.614, p0.0018), but not following
SOT (OR1.087, p0.83). Graft rejection was recorded for 11.53% of SOT recipients
and the odds ratio of rejection associated with CMV was 2.71 (p0.0007). Average
hospitalisation costs were €45,700 for HSCT and €32,200 for SOT. CMV disease was
associated with increases in costs by 90.37% (p0.0001) for HSCT and 86.14%
(p0.0001) for SOT. CONCLUSIONS: CMV disease is associated with substantial
increases in probability of graft rejection, mortality and hospitalisation costs in
French transplant recipients. The costs and serious adverse events of antiviral
therapy for CMV prophylaxis or pre-emption add to this burden.
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OBJECTIVES: No cure for HIV currently exists, however antiretroviral (ARV) drugs
can control disease progression. The objective of this study was to carry out a
mixed-treatment comparison (MTC) of randomized controlled trials (RCTs) to as-
sess the relative efficacy and safety of ARV drugs used in treatment-experienced
(TE) patients. MTCs synthesise available evidence by combining direct and indirect
comparisons. METHODS: All phase II and III RCTs published in the past five years,
assessing the efficacy of etravirine (ETR), maraviroc (MVC) and raltegravir (RAL) in
combination with optimized background therapy (OBT) compared to OBT alone in
TE HIV patients were identified. Data on patient characteristics, CD4 cell count
changes, virological suppression (percentage of HIV RNA 50 copies/mL and 400
copies), common adverse events (diarrhoea, nausea), discontinuations and deaths
were extracted. A Bayesian fixed-effect mixed-treatment network analysis was
performed on efficacy and safety outcomes at 48 and 96 weeks. RESULTS: Twenty-
two studies were identified; six were included in the MTC network based on data
availability (i.e. BENCHMRK 1 and 2, DUET 1 and 2 and MOTIVATE 1 and 2). All
treatments showed increased efficacy compared to OBT. MVC twice daily was as-
sociated with an increased virological suppression (mean odds ratio 1.66 for400
copies and 1.88 for  50 copies) and larger CD4 count increase (mean change of 40
cells/mL) compared to ETR at 48 weeks. MVC’s superior efficacy to ETR was main-
tained at week 96. MVC was no different to RAL at week 48 but superior to RAL at 96
weeks for both efficacy outcomes. For safety outcomes, no differences between
treatments were found.CONCLUSIONS: In the absence of head-to-head trials com-
paring active drugs, this study provides information on the relative efficacy of each
regimen. It confirms the significant clinical value of MVC compared to ETR and RAL
in treatment-experienced patients.
PIN5
EFFICACY OF CEFTAROLINE FOSAMIL AND OTHER INTRAVENOUS ANTIBIOTICS
IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA (CAP): A
NETWORK META-ANALYSIS (NMA)
Medic G1, Karabis A1, Borrill J2, Worrall J3, Bergman G1
1MAPI Consultancy, Houten, The Netherlands, 2AstraZeneca, Macclesfield, UK, 3AstraZeneca UK
Ltd., Luton, UK
OBJECTIVES: Ceftaroline fosamil, the prodrug of the active metabolite ceftaroline,
is a broad-spectrum intravenous cephalosporin with bactericidal activity against
common pathogens causing CAP. The objective was to evaluate the efficacy of
ceftaroline fosamil compared with other antibiotics recommended for initial em-
piric treatment of adults admitted to hospital with moderately severe CAP.
METHODS: MEDLINE, Medline-In-Process, EMBASE and the Cochrane Controlled
Trials Registry were searched to identify published trials in which ceftaroline fos-
amil, ampicillin/sulbactam, ceftriaxone (1g or 2g q24h), cefuroxime, cefotaxime,
co-amoxiclav, ertapenem, levofloxacin and moxifloxacin were used to treat hospi-
talised patients with CAP. Primary outcomes were clinical success at test-of-cure
visit in the modified intention-to-treat (MITT) and clinically evaluable (CE) popula-
tions using a NMA with uninformative priors. Clinical success for each antibiotic
was reported with 95% credible intervals (CrI95%). A fixed effects model was used.
RESULTS: Twelve studies (24 treatment arms) with a total of 4,647 patients with
CAP were included in the analysis. Five studies involving 2,888 patients were in-
cluded in the MITT analysis and 9 studies with 3,182 patients in the CE analysis.
The pooled clinical success rates (CrI95%) in the MITT population for each antibi-
otic were: ceftaroline fosamil 75.5% (71.3% to 79.4%), ceftriaxone 68.2% (65.6% to
70.6%), levofloxacin 74.3% (67.3% to 80.4%), and moxifloxacin 73.8% (67.1% to
79.7%). Clinical success rates (CrI95%) in the CE population were ceftaroline fosamil
85.9% (81.4% to 89.6%), ceftriaxone 79.7% (77.3% to 82.0%), co-amoxiclav 64.6%
(46.9% to 78.4%), ertapenem 79.8% (70.3% to 87.0%), levofloxacin 85.5% (77.2% to
91.2%), and moxifloxacin 81.7% (75.2% to 86.9%). CONCLUSIONS: The results sug-
gest that ceftaroline fosamil may be at least as effective as other antibiotics used in
the initial empiric treatment of adults admitted to hospital with CAP. This analysis
is limited by the small number of studies that were found, making controlling for
heterogeneity challenging.
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OBJECTIVES: Chronic Hepatitis C virus (HCV) infection is one of the silent global
epidemics with significant unmet need and disease burden. One of the major lim-
itations of current treatments is the need for 12 or 6 months of Interferon based
therapy, which has tolerability and toxicity issues for many patients. During last
2-3 years several new agents have been tested in clinic, which have shown prom-
ising results as non-interferon based therapy. Goal of this study was to review the
clinical efficacy and safety profile of non-interferon based therapies for HCV
treatment. METHODS: We searched the MEDLINE, and abstracts from AASLD and
EASL until May 2012. Studies were selected for clinical trials on direct acting agents
for HCV. Primary endpoints reviewed were Sustained Viral Response (SVR). Toxic-
ity was evaluated as secondary endpoint. Aggregated data were further analyzed to
understand comparative safety and efficacy. RESULTS: Until May 2012, results of
five eligible HCV clinical trials for interferon free regimens were available. Overall,
treatment with combination of protease and polymerase inhibitor showed dra-
matic viral load reduction after 2 weeks of treatment. The combination of PSI-7977
and PSI-938 showed 93% viral clearance after 14 days (n16). The combination of
RG7227 and RG7128 demonstrated 5.1 log reduction in viral load in treatment naive,
and 4.9 log reduction in null responder patients after 14 days of treatment. The
combination of BMS-790052 and BMS 650032 showed 36.3% 24 week SVR in null
responder patients. One study evaluating VX-222 and Telaprevir combination was
discontinued due to viral breakthrough. Several studies are currently on-going
whose data would be available in 2012-2013. CONCLUSIONS:Non-interferon based
therapies have shown impressive viral load reduction in short term studies. How-
ever, more data for SVR, viral breakthrough and resistance is needed to confirm
their safe use in HCV infected population.
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OBJECTIVES: Ceftaroline fosamil, the prodrug of the active metabolite ceftaroline,
is a novel intravenous cephalosporin with in vitro bactericidal activity against
resistant Gram-positive pathogens, including methicillin-resistant Staphylococcus
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